企业QQ
官方微信
TruSightTumor170,anext-generationsequencingassaydesignedtocover170genesassociatedwithcommonsolidtumors,isanenrichment-basedtargetedpanelthatsimultaneouslyanalyzesDNAandRNA,coveringawiderangeofgenesandvarianttypes.Thecomprehensivenatureprovideslaboratorieswithadeepviewintothegeneticsofcancer.
| AssayTime | ~2days(LibraryPrep) |
| Hands-OnTime | ~10.5hours |
| InputQuantity | 40ngDNAand/orRNA |
| Method | TargetedRNASequencing,TargetedDNASequencing |
| VariantClass | SingleNucleotidePolymorphisms(SNPs),GeneFusions,SomaticVariants,StructuralVariants,Insertions-Deletions(indels),CopyNumberVariants(CNVs) |
| SpecializedSampleTypes | FFPE,LowInput |
| SystemCompatibility | NextSeq550,NextSeq500,HiSeq2500 |
| Technology | Sequencing |
| SpeciesCategory | Human |
| CancerType | SolidTumor |
ResultsofanalysisindicatethatTruSightTumor170,withcomprehensivecoverageofcancer-relatedgenes,showshighconcordancewithwholeexomesequencingforaccurateassessmentoftumormutationalburden.
LearnMore
StandardextractionsfromFFPEembeddedsamplesprovidesufficientmaterial(40ng)in>95%ofsamplesthatwereextractedbyIllumina.ThisdatashowsthattheTruSightTumor170panelisarobustassaythatgeneratespassingsampleQCdatain>85%ofsampleswithvaryingquality,andin>95%ofsamplesthathavequalitymetricsthatfallwithintherecommendationsforthekit.
LearnMore
TruSightTumor170canachievehighsensitivityandspecificityforthedetectionofsomaticvariants(smallvariantsandCNVs)fromDNAextractedfromFFPEtissues.
LearnMore
ThroughexamininglimitofdetectioninthecontextofRNAexpression,thisstudyshowsthatTruSightTumor170provideshighsensitivityandspecificityinRNAvariantcallingdownto5copiesoftranscriptperngofinput.
LearnMore